Rein Therapeutics (RNTX) Stock Price, News & Analysis

Company Overview

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious pulmonary and fibrotic diseases. The company’s research is centered on therapies intended to address the underlying biological mechanisms that drive tissue scarring and chronic disease progression.

Its lead investigational product is bexotegrast, an oral small-molecule inhibitor of the integrins αvβ1 and αvβ6. Rein Therapeutics is evaluating bexotegrast in clinical development for conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic disease that affects the bile ducts and can lead to liver damage. Bexotegrast remains an investigational therapy and has not been approved for commercial use.

The company’s development strategy is focused on advancing therapies for diseases with significant unmet medical needs, with clinical activities directed toward relevant patient populations and healthcare markets. Rein Therapeutics is headquartered in the United States. Publicly available information about the company’s broader product pipeline and leadership history is limited.

Key Stats

• Today's Range: $0.59 to $0.63
• 50-Day Range: $0.55 to $0.89
• 52-Week Range: $0.54 to $2.10
• Volume: 307,123 shs
• Average Volume: 432,406 shs
• Market Capitalization: $52.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Rein Therapeutics Stock Analysis - MarketRank™

Rein Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 585th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Rein Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Rein Therapeutics has a consensus price target of $6.00, representing about 890.1% upside from its current price of $0.61.

Amount of Analyst Coverage

Rein Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rein Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rein Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rein Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.83% of the float of Rein Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rein Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rein Therapeutics has recently increased by 19.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rein Therapeutics does not currently pay a dividend.

Dividend Growth

Rein Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Rein Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Rein Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rein Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Rein Therapeutics is held by insiders.

Percentage Held by Institutions

90.89% of the stock of Rein Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RNTX
• CIK: 1420565
• Web: www.reintx.com
• Phone: (737) 802-1989
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rein Therapeutics: $6.00
• High Price Target: $8.00
• Low Price Target: $4.00
• Potential Upside/Downside: +890.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -63.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.27
• Quick Ratio: 4.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.06 per share
• Price / Cash Flow: 10.86
• Book Value: ($1.07) per share
• Price / Book: -0.57

Miscellaneous

• Outstanding Shares: 86,270,000
• Free Float: 84,973,000
• Market Cap: $52.28 million
• Optionable: N/A
• Beta: 1.47